Crowdonomics
All companies
CytexOrtho logo

CytexOrtho

Operating

Cytex Therapeutics, Inc.

Healthcare · Durham, NC · Founded 2006

One biodegradable implant, full restoration

Post-money valuation ⓘ
$18.7M
As of Jan 2023 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$465,929
Crowd $304K · Private $162K · 3 rounds since 2021
Latest share price
$2.00
Reg CF · Common Stock · Oct 2022 offering price

Financials

FY2021–FY2024 · from SEC filings · hover any figure for its source
$1.8M
−$23K
2021
$1.1M
−$622K
2022
$1.3M
−$1.2M
2023
$1.4M
−$1.1M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 unaudited
FY2022 unaudited
FY2023 unaudited
FY2024 unaudited
Income statement
Revenue
$1,836,602
$1,052,219
$1,284,927
$1,366,195
Cost of goods sold
$1,263,476
$731,921
$858,498
$985,982
Gross margin
31%
30%
33%
28%
Net income
-$22,653
-$621,726
-$1,214,922
-$1,069,206
Taxes paid
$0
$14,219
-$10,845
-$2,186
Balance sheet
Cash
$489,299
$474,993
$170,770
$249,960
Accounts receivable
$66,611
$47,914
$57,591
$45,658
Total assets
$626,138
$719,644
$385,279
$536,278
Short-term debt
$144,543
$193,580
$192,787
$231,628
Long-term debt
$250,000
$490,492
$575,135
$957,036
Total liabilities
$394,543
$684,072
$767,922
$1,188,664
Other
Headcount
8
9
8
8

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$18.2M
pre-money
Reg CF · Common · Oct 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$2.00$1.00$0.3075
Dec 2021Oct 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Raised $125KInvestors 2
Raised $304K / $1.1MInvestors 258Post-money $18.7M

Team

11 people
Bradley Estes, PhDFounder
CEO

Brad has held various research and development positions in the medical device industry in addition to acting as a consultant for both small, start-up and large, established medical device companies. Brad started his career in the orthopedic division of Medtronic and spent almost a decade commercializing products in key growth markets, including products with difficult regulatory paths. In total, he has over 25 years of industry experience in medical device design, research and development of orthopedic devices, FDA interactions for the purposes of regulatory approvals, and launching novel orthopedic inventions from lab to marketplace. Dr. Estes leads the Cytex team in applying regenerative medicine techniques to novel solutions for unmet needs in orthopedic medicine. Dr. Estes is an inventor with over 50 patents associated with medical devices. Dr. Estes earned a Ph.D. in Biomedical Engineering from Duke University.

Farshid Guilak, PhDFounder
Board Chair, Co-founder

Farsh is a Professor of Orthopaedic Surgery at Washington University, Director of Research for the St. Louis Shriners Hospitals for Children, and co-director of the Washington University Center of Regenerative Medicine. His laboratory is currently pursuing a multidisciplinary approach to investigate the etiology and pathogenesis of various musculoskeletal diseases – particularly arthritis – as a basis for developing new bioengineering-based therapies. He has published over 300 articles in peer-reviewed journals and has co-edited four books. He is the past-president of the Orthopaedic Research Society and former editor-in-chief of the Journal of Biomechanics. He has won several national and international awards for his research. In addition to his many academic responsibilities, Dr. Guilak is the current Chairman of the Board at CytexOrtho.

Franklin Moutos, PhDFounder
VP Technology

Frank is also one of the co-founders of CytexOrtho. He has an extensive background and experience in medical applications of textiles and biomaterials, specifically those used in medical devices. Dr. Moutos has been involved in the development of new technologies for the treatment of osteoarthritis and related degenerative joint diseases using various biomaterials, stem cells, and gene therapies. During his pursuit of his Ph.D. while conducting various research in tissue regeneration, Frank helped develop the woven textile methods and processes that are now incorporated into the novel, CytexOrtho 3D printed implant. Dr. Moutos is a multiple patent holder, and he received his Ph.D. in Biomedical Engineering from Duke University. No Social Media accounts

Bradley T. Estes, Ph.D.
CEO and Director
Christine Estes
Director of Business and Finance

Christine oversees daily business operations, finance, and federal compliance efforts. Ms. Estes has over 10 years of experience in financial management and has held various positions in small and large businesses, including software consulting, management training, tax preparation, and human resource roles. Ms. Estes has extensive training and acquired expertise in federal grants management and holds a B.S. in Mathematics from Vanderbilt University.

Nikhil Gheewala, PhD
Director of Product Development

Nikhil has over 15 years of experience in tissue engineering research and product development in both academic and small business environments. In his current position at CytexOrtho, he draws upon his R&D experience in controlled GLP, GMP and cGMP quality system environment to drive complex products through preclinical and clinical translation towards commercial manufacturing. Nikhil received his Ph.D. in Bioengineering from Rice University.

Vincent Willard, PhD
Director of Research

Vince has extensive experience in molecular and stem cell biology toward developing engineered cartilage with specific genetic, biochemical, and mechanical properties. At CytexOrtho, Dr. Willard spearheads research efforts on current and next generation technology. Through his 15+ years of research experience, Dr. Willard has led numerous interdisciplinary teams to complete projects in a variety of bioengineering subjects including articular cartilage and fibrocartilage biology and tissue engineering, orthopaedic tissue biomechanics and interspecies comparisons, pluripotent stem cell differentiation, and gene therapy. Dr. Willard earned his Ph.D. in Biomedical Engineering from Rice University.

Barry Myers, MD, PhD
Non-executive director

Barry has considerable experience in both business and academic leadership. In addition to his current roles as an Executive-in-Residence at Pappas Ventures and as a Professor of Biomedical Engineering at Duke, Dr. Myers maintains an active consulting practice, advising clients concerned with product safety. He is recognized as a world leader in injury research and product safety, with over 100 publications. Rounding out this experience, he has also served as past Managing Director of the Duke Office of Licensing and Ventures. Dr. Myer's scientific and business background add significant insight for both product and business development as a member of the Board of Directors at CytexOrtho.

Dave Nolan
Non-executive Director

Dave is a results-oriented leader with over 20 years of business development experience. Formerly of Zimmer Biomet, Dave successfully executed organic and inorganic growth strategies to deliver strong operating performance and stock price appreciation. Mr. Nolan provides key business development experience to the CytexOrtho Board of Directors due to his in-depth knowledge of domestic and international sales and operations and significant experience in strategic planning, financial management, mergers and acquisitions, and business integration. No Social Media accounts

Show 2 more people
Laura Tormey
Manager of Product Development

Laura has significant engineering experience in the biotechnology industry with expertise in development and manufacturing of polymer-based devices for clinical applications. She also has extensive experience developing and validating systems for manufacturing and quality control of polymer structures. In her role at CytexOrtho, she draws upon these experiences to design manufacturing processes and quality procedures to produce scaffolds (our implants) that support cartilage tissue growth in pre-clinical and human studies. Laura has a BS in Mechanical Engineering from the University of Alaska, and she is currently pursuing a MNAE (Masters of Nanoengineering) at North Carolina State University.

Tara Boykin
Administrative Assistant

Tara serves a variety of roles at CytexOrtho including bookeeping, report and documentation preparation, and office support. Ms. Boykin has 10+ years of experience in areas of data management, payroll administration, research finance, records management, and financial and accounting software.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 3 of 4 annual reports (FY2022–FY2025)

258 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRMay 8, 20250001943908-25-000002
    EDGAR
  • Form C-ARMay 2, 20250001665160-25-000970
    EDGAR
  • Form DJan 10, 20250001943908-25-000001
    EDGAR
  • Form C-ARApr 29, 20240001665160-24-000630
    EDGAR
  • Form C-ARMay 1, 20230001665160-23-001128
    EDGAR
  • Form C-UJan 27, 20230001665160-23-000144
    EDGAR
  • Form COct 26, 20220001665160-22-002814
    EDGAR
Source: ManualCIK 0001943908DEShare price $2.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.